medigraphic.com
Anales de Otorrinolaringología Mexicana

2014, Number 1

<< Back Next >>

Otorrinolaringología 2014; 59 (1)

Immunological Changes in the Treatment of Ameloblastoma Favored by the Adipocyte Implant

López LE, López DE, Salazar VMR, García BL, Robles MB, Cervantes MR, Arcaute VF, Jiménez HEG

Language: Spanish
References: 21
Page: 72-78
PDF size: 1123.32 Kb.


ABSTRACT

This paper repors the case of a patient with basal cell ameloblastoma. The treatment of choice is the radical surgery; however, a high percentage of results has bias because patients do not accept these surgical procedures, thus currently the survival of patients is unknown. Therefore, it was decided to give an observational therapy, consisting of a surgical procedure less aggressive than radicalization (Caldwell-Luc procedure), associated with the implantation of adipocytes in the operated region, inasmuch they have reparative action and they can cloister the tumor.Accordingly, we decided to obliterate the maxillary sinus with fat, waiting changes in the body’s immune response. As adjuvant therapy, we indicated a dietary supplement that offers to modify individual’s immune process, so we used as an immunomodulator the human transfer factor. From the histopathological point of view the findings were basal cell ameloblastoma in the first two studies and in the other two basal cell adenoma of minor salivary gland with no evidence of malignancy. In the post-implant surgical revision of adipocytes, we saw the confinement of tumor; the final pathology report changed in diagnosis. The pathology of the maxillary sinus was malignant and in the final study it was benign.


REFERENCES

  1. Bachur R y col. Ameloblastoma: Caso clínico. Argentina: Bachur. (Actualizado 2012 Junio 01; consultado en 2012 Junio 06) Disponible en: http://www.bachur.com.ar/ caso_clin_10.htm

  2. Nakamura N, et al. Comparison of long-term result between different approaches to ameloblastoma. Oral surgery, Oral medicine, Oral pathology, Oral Radiology & Endodontics 2002;93:13-20.

  3. Vargas Soto G y col. Tratamiento de los ameloblastomas. Análisis de 26 casos. Revista Mexicana de Cirugía Bucal y Maxilofacial 2010;6:66-72.

  4. López Lizárraga E. Otorrinolaringología práctica. México: Cuellar Ayala, 2010;127.

  5. Nakamura N, Higuchi Y, Tashiro H, Ohishi M. Marsupialization of cystic ameloblastoma: A clinical and histopathologic study of the growth characteristics before and after marsupialization. J Oral Maxillofac Surg 1995;53:748-754.

  6. Urquiola FA. Cirugía del seno frontal. Fundación Arauz Otorrinolaringología. Argentina, 2006. Disponible en: http:// www.farauzorl.org.ar/info-pacientes-y-medicos/medicos/ monografias-carrera-especialistas-uba/monografiacirugia- del-seno-frontal

  7. Hassan R. History of frontal sinus surgery. Arch Otolaryngol Head Neck Surg 2000;126:98-99.

  8. López Lizárraga E. Otorrinolaringología práctica. México: Cuellar Ayala, 2010;108-109.

  9. Borrego F, Frias M, Aguado R, Peña J. Células y órganos del sistema inmune. Inmunología en línea. Universidad de Córdoba y Hospital Reina Sofía de Córdoba. (Consultado en 2012 Noviembre 05) Disponible en: http://www. inmunologiaenlinea.es/index.php?option=com_content&v iew=article&id=60:celulas-tipo-inmune&catid=38:celulasy- organos&Itemid=126

  10. Ojeda M, et al. Dialyzable leuococyte extract (DLE) reduces lipopolysaccharide-induced tumor necrosis factor secretion in human leucocytes. Biotherapy, 1996;9:163-17.

  11. Rozzo SJ, Kirkpatrick CH. Purification of transfer factor. Mol Immunol 1992;29:167-182.

  12. Sánchez D, y col. Factores de transferencia en la terapéutica médica. Med Clin 2011;137:273-277.

  13. Huerta LJ. Factor de transferencia: Una alternativa en el tratamiento de las enfermedades alérgicas. Alergia e Inmunol Pediatr 2002;11: 4.

  14. Gómez Vera, et al. Transfer Factor. Alergia Mex 2010;57:208- 214.

  15. Salazar Villa R, Zambrano Villa S. Uso del factor de transferencia en el asma bronquial alérgica. Rev Alergia Mex 1993;XL:42-45.

  16. Cabezas-Quiroga R. Inmunoterapia con factor de transferencia en pacientes con herpes zoster. Biotecnol Aplicada 1990;7:52-56.

  17. Correa-Meza BE, Pérez de la Mora C, et al. Transfer factor and acyclovir in the treatment of herpes zoster. Immunopharmacology 1998;20:521-535.

  18. Lawrence H, Borkowsky W. Transfer factor- Current status and future prospects. Biotheraphy 1996;9:1-5.

  19. Alvarez A, Kirpatrick CH. Profiles of cytokine production in recipients of transfer factor. Biotherapy 1996;9:55-59.

  20. Candanosa E, Estrada Parra S, y col. Empleo del factor de transferencia de origen bovino en el modelo tumoral murino melanoma B16. Vet Mex 1997;28:93-99.

  21. Berron Perez, et al. Indication, usage and dosage of transfer factor. Rev Alergia Mex 2007;54:134-39.




2020     |     www.medigraphic.com